Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma

Preclinical studies indicate that vorinostat (suberoylanilide hydroxamic acid or SAHA) inhibits histone deacetylase (HDAC) activity, increases acetylated histones H2a, H2b, H3, and H4, and thereby induces differentiation and apoptosis in a variety of tumour cell lines, including murine erythroleukae...

Descripción completa

Detalles Bibliográficos
Autor principal: O'Connor, O A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360773/
http://dx.doi.org/10.1038/sj.bjc.6603464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360773/
http://dx.doi.org/10.1038/sj.bjc.6603464

Ejemplares similares